Skip to main content

Table 3 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. b. Participants with MDR-TB Eligible for Short Course Treatment Who Had Not Previously Received MDR-TB-Active Treatment, by DST Performed

From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Resistance Status Xpert Only, N = 267 2nd-Line LPA Only,a N = 217 Testing R, FQ, INJ, Z, and E, N = 210b Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 200b
  # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c
Eligible for Short Course 267 / 267 (100) 67 / 217 (30.9) 11 / 210 (5.2) 10 / 200 (5.0)
Resistant to FQ or INJ N/A 150 / 217 (69.1) 143 / 210 (68.1) 135 / 200 (67.5)
Resistant to Z or E N/A N/A 194 / 210 (92.4) 185 / 200 (92.5)
Resistant to FQ, INJ, Z, or E N/A N/A 199 / 210 (94.8) 189 / 200 (94.5)
Resistant to FQ, INJ, Z, E, Eto, or Cfz N/A N/A N/A 190 / 200 (95.0)
  1. a2nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
  2. bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
  3. cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows